We had a Press Release on PrognostiCheck(R) titled “ Who Will Live or Die of Breast Cancer? PrognostiCheck® Reveals Health of Cell Membranes ”
Here is the abstract
IPGDx, LLC, a MI based medical technology company’s product PrognostiCheck® uses phase angle from impedance analysis to detect the presence and severity of breast cancer, the effectiveness of treatment and survival of breast cancer patients who have the disease.
In a recent study of 259 breast cancer patients, 81 that were newly diagnosed, 178 that had received prior treatment; 56 with stage I disease at diagnosis, 110 with stage II, 46 with stage III and 34 with stage IV. Their ages ranged from 25 to 74 years old. The median phase angle was 5.6 degrees. Patients with phase angle less than or equal to 5.6° had a median survival of only 23.1 months , while those greater than 5.6° had 49.9 months.
PrognostiCheck® is a scoring system that interprets a measured electrical value that illustrates the health of the cell membrane.It can be used to provide critically important information to patients, their families and physicians on survival in breast cancer and all other diseases.
Read more about the prognosis in the press release here
Tags:
Breast Cancer,
Breast Cancer prognosis,
Measure Prognosis,
Phase Angle,
Prognosis